Celldex Therapeutics, Inc. Share Price Deutsche Boerse AG
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 258.87Cr 227.91Cr 210.22Cr 196.61Cr 368.38Cr 24TCr 375.25Cr 2.53TCr 978.52Cr 12TCr 971.92Cr 950.84Cr 42TCr | P/E 2026 * |
-7.6x | P/E 2027 * | -7.55x |
|---|---|---|---|---|---|
| Enterprise Value | 200.46Cr 176.48Cr 162.78Cr 152.25Cr 285.26Cr 19TCr 290.58Cr 1.96TCr 757.72Cr 9.32TCr 752.61Cr 736.29Cr 32TCr | EV / Sales 2026 * |
761x | EV / Sales 2027 * | 174x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +2.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.56% | +823.22% | - | - | 258.87Cr | |
| +2.56% | +7.12% | -7.30% | +1.26% | 4.45TCr | |
| -0.77% | +7.01% | +321.76% | +578.85% | 3.6TCr | |
| +0.81% | +6.42% | +4.78% | +55.22% | 3.07TCr | |
| +7.58% | +7.88% | +16.11% | -13.89% | 2.86TCr | |
| +7.60% | -1.03% | +14.05% | +20.82% | 2.3TCr | |
| +0.38% | +3.59% | - | - | 1.48TCr | |
| +7.44% | +11.13% | +61.12% | +125.65% | 1.35TCr | |
| +2.73% | +7.16% | +11.00% | +19.38% | 1.3TCr | |
| +1.50% | +3.57% | +94.15% | +96.83% | 1.26TCr | |
| Average | +3.24% | +2.88% | +64.46% | +110.52% | 2.41TCr | |
| Weighted average by Cap. | +3.06% | +3.11% | +71.11% | +128.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 26.35L 23.2L 21.4L 20.01L 37.49L 25Cr 38.19L 2.57Cr 99.59L 12Cr 98.92L 96.78L 43Cr | 1.2Cr 1.05Cr 97.14L 90.86L 1.7Cr 112.76Cr 1.73Cr 12Cr 4.52Cr 56Cr 4.49Cr 4.39Cr 193.52Cr |
| Net income | -33Cr -29Cr -27Cr -25Cr -47Cr -3.11TCr -48Cr -322.11Cr -124.76Cr -1.53TCr -123.92Cr -121.23Cr -5.34TCr | -37Cr -33Cr -30Cr -28Cr -53Cr -3.49TCr -54Cr -361.56Cr -140.05Cr -1.72TCr -139.1Cr -136.08Cr -5.99TCr |
| Net Debt | -58Cr -51Cr -47Cr -44Cr -83Cr -5.51TCr -85Cr -570.04Cr -220.79Cr -2.72TCr -219.31Cr -214.55Cr -9.45TCr | -51Cr -45Cr -41Cr -39Cr -72Cr -4.78TCr -74Cr -495.16Cr -191.79Cr -2.36TCr -190.5Cr -186.37Cr -8.21TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
